LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package

LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program.

Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021.

LEXEO TX Announces Licensing Agreement
Download P • 170KB


©2020 by Lexeo Therapeutics

430 East 29th Street, 14th Floor
New York, New York


(212) 547-9879